| Patents for C07K 16 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies (149,320) |
|---|
| 05/11/2004 | US6734174 Modulators of the function of receptors of the TNF/NGF receptor |
| 05/11/2004 | US6734168 Endothelial monocyte activating polypeptide II: a mediator which activates host response |
| 05/11/2004 | US6734160 Nucleotide sequences coding polypeptide for use in the treatment of diabetes |
| 05/11/2004 | US6734003 Phosphodiesterase 10 |
| 05/11/2004 | US6733990 Useful for the treatment of immune, hematologic, fibrotic, hepatic, and respiratory disorders such as asthma using g-protein coupled receptors (gpcr) |
| 05/11/2004 | US6733981 Antibodies to interleukin-1 β converting enzyme like apoptosis protease-3 and 4 |
| 05/11/2004 | US6733980 Diagnostic method for detection of molecular forms of eosinophilic cationic protein (ISO-ECPS) |
| 05/11/2004 | US6733978 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| 05/11/2004 | US6733752 Antibody specifically binds to p185; breast cancer |
| 05/11/2004 | US6733743 Methods to impair hematologic cancer progenitor cells and compounds related thereto |
| 05/11/2004 | US6733130 Method for refracting and dispensing electro-active spectacles |
| 05/11/2004 | CA2302033C Methods and compositions for enhanced wound healing |
| 05/06/2004 | WO2004038416A1 Diagnostics and therapeutics for diseases associated with human g-protein coupled receptor 6 (gpr6) |
| 05/06/2004 | WO2004038407A2 Diagnostics and therapeutics for diseases associated with human g-protein coupled receptor 12 (gpr12) |
| 05/06/2004 | WO2004038406A2 Diagnostics and therapeutics for diseases associated with human g protein-coupled receptor 42 (gpr42) |
| 05/06/2004 | WO2004038405A2 Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 43 (gpr43) |
| 05/06/2004 | WO2004038028A2 Hepatitis x virus antigen |
| 05/06/2004 | WO2004038022A1 Method of examining swine genetic resistance to rna virus-origin disease |
| 05/06/2004 | WO2004038010A1 Method of obtaining cell lines in a protein-free medium and cell lines thus obtained |
| 05/06/2004 | WO2004038003A2 Human polypeptides encoded by polynucleotides and methods of their use |
| 05/06/2004 | WO2004038002A2 Modulation of dendritic cell function and other cellular responses mediated by defensin compositions |
| 05/06/2004 | WO2004037999A2 A34 and a33-like 3 dna, proteins, antibodies thereto and methods of treatment using same |
| 05/06/2004 | WO2004037972A2 Endogenous retrovirus up-regulated in prostate cancer |
| 05/06/2004 | WO2004037863A1 Antibody and utilization of the same |
| 05/06/2004 | WO2004037862A1 Special igy of resist allergic and its preparation |
| 05/06/2004 | WO2004037861A2 Neutralizing antibodies against gdf-8 and uses therefor |
| 05/06/2004 | WO2004037860A1 Epididymis-specific gene as potential contraceptive target |
| 05/06/2004 | WO2004037857A1 Bfk protein as therapeutic molecules |
| 05/06/2004 | WO2004037847A2 Hiv envelope-cd4 complexes and hybrids |
| 05/06/2004 | WO2004037282A1 The use of cytochrome p450 enzyme cyp2wi as a drug traget for cancer therapy |
| 05/06/2004 | WO2004037209A2 METHODS TO PREVENT TUMOR RECURRENCE BY BLOCKADE OF TGF-β |
| 05/06/2004 | WO2004037205A2 LOW DOSE METHODS FOR TREATING DISORDERS IN WHICH TNFα ACTIVITY IS DETRIMENTAL |
| 05/06/2004 | WO2004037198A2 Antibody-mediated induction of tumor cell death |
| 05/06/2004 | WO2004014953A3 Anti-myelin associated glycoprotein (mag) antibodies |
| 05/06/2004 | WO2004008140A3 Plasma urotensin in human heart failure |
| 05/06/2004 | WO2003104281A8 Antibodies to adipose tissues |
| 05/06/2004 | WO2003050502A9 Prospective identification and characterization of breast cancer stem cells |
| 05/06/2004 | WO2003046008A9 Therapeutic use of antibodies and fragments thereof binding primate ifn-gamma |
| 05/06/2004 | WO2003025019A9 Anti-pdgf antibodies and methods for producing engineered antibodies |
| 05/06/2004 | WO2003011903A3 Identification of specific tumor antigens by means of the selection of cdna libraries with sera |
| 05/06/2004 | WO2003009817A9 Stable lyophilized pharmaceutical formulation of igg antibodies |
| 05/06/2004 | WO2002092788A9 Cytotoxic peptides and peptidomimetics based thereon, and methods for use thereof |
| 05/06/2004 | WO2002074251A9 Monoclonal antibody therapy for pancreas cancer |
| 05/06/2004 | WO2001074296A3 Treatment of non-solid mammalian tumors with vascular endothelial growth factor receptor antagonists |
| 05/06/2004 | US20040088756 Identifying diseases resistance gene in plants |
| 05/06/2004 | US20040087784 Neuronal serine-threonine protein kinase |
| 05/06/2004 | US20040087778 Modified peptides as therapeutic agents |
| 05/06/2004 | US20040087777 Humanized antibodies that recognize beta amyloid peptide |
| 05/06/2004 | US20040087774 Comprises tumor necrosis factor receptor associated factor-(TRAF) inhibitor for diagnosis, prevention and tratment of tumors associated wit h epstein-barr virus |
| 05/06/2004 | US20040087772 Tumor marker polypeptide for diagnosis, prevention and treatment of cell proliferative disorders; antitumor/anticarcinogenic agents |
| 05/06/2004 | US20040087770 Viral peptide for use in diagnosing, preventing and treating sepsis and meningitis; microbiocides; vaccine development |
| 05/06/2004 | US20040087649 Cytotoxic agents comprising taxanes and their therapeutic use |
| 05/06/2004 | US20040087522 Genetic vaccines for the production of chicken egg-yolk antibodies against enterotoxigenic escherichia coli and other pathogens |
| 05/06/2004 | US20040087481 Modulation of cholesteryl ester transfer protein (CETP) activity |
| 05/06/2004 | US20040087478 Discovering pain regulating substances; incubating with then measuring binding to cell synthesized peptide or protein |
| 05/06/2004 | US20040087025 Transfering genetic material into proliferating lymphocytes using phorbol ester, calcium ionophores and lymphocyte receptor/CD3 complexes; gene therapy |
| 05/06/2004 | US20040086979 Preparing monoclonal antibody with reduced immunogenicity; diagnostic tools; immunotherapy |
| 05/06/2004 | US20040086977 Fusion polypeptides of human serum albumin and a therapeutically active polypeptide |
| 05/06/2004 | US20040086976 Genetically engineered erythropoietin for diagnosis, prevention and treatment of thrombis, cancer, neovascularization, inflammation and autoimmune diseases |
| 05/06/2004 | US20040086973 Calmodulin-dependent protein kinase inhibitor for treatment and prevention of nervous system disorders |
| 05/06/2004 | US20040086971 Comprises nucleotide sequences coding extracellular matrix protein for prevention and treatment of inflammatory, immune and thrombotic disorders |
| 05/06/2004 | US20040086966 Comprises g-protein couple receptor polypeptide for diagnosis and treatment of cell proliferative disorders; gene therapy; immunotherapy |
| 05/06/2004 | US20040086947 Deep vein thrombosis; respiratory system disorders; anticoagulants; measuring concentration of fibrinopeptides in sample; immunoassay |
| 05/06/2004 | US20040086946 Methods of isolation of active compounds and activated targets |
| 05/06/2004 | US20040086942 Comprises peptide mimetic which competes for binding site of immunoglobulin receptor and prevents and treats allergic disorders |
| 05/06/2004 | US20040086935 Comprises nucleotide sequences coding heterodimeric receptors for identifying modulator of tumor metastasis and inflammation |
| 05/06/2004 | US20040086934 Comprises striamin polypeptide for identifying modulator for treatment and prevention of cardiovascular, tumor and muscle disorders |
| 05/06/2004 | US20040086933 Protein and gene involved in myocyte differentiation |
| 05/06/2004 | US20040086923 Comprises polypeptide with carbamoyl phosphate synthase (CPS) activity for identifying modulators which prevent and/or treat cancer and metabolic disorders |
| 05/06/2004 | US20040086913 Human genes and gene expression products XVI |
| 05/06/2004 | US20040086905 Lipid-associated molecules |
| 05/06/2004 | US20040086902 Comprises nucleotide sequences coding fructosyltransferase for preparation of fructooligosaccharides and difructose dianhydrides for use as dietetic food or animal feed additive |
| 05/06/2004 | US20040086882 Comprises nucleotide sequences coding mutant multidrug resistance gene (MDR) which confers side effect reduction to anticancer drugs |
| 05/06/2004 | US20040086877 Multi-mode directi memory access controller and method |
| 05/06/2004 | US20040086863 Comprises pleckstrin homology domain-interacting protein (PHI Protein) for identifying modulator and treatment for cancer and insulin response disorders |
| 05/06/2004 | US20040086859 Identification of a dual specificity phosphate: dusp-10 |
| 05/06/2004 | US20040086858 Identification of new human gaba transporter |
| 05/06/2004 | US20040086534 Method of decreasing the severity or frequency of a relapse of multiple sclerosis |
| 05/06/2004 | US20040086525 Polynucleotide sequences of C. pneumoniae for use in preventing and treating Chlamydia infection |
| 05/06/2004 | US20040086513 Antibodies for preventing and treating attaching and effacing escherichia coli (aeec) associated diseases |
| 05/06/2004 | US20040086512 Multimerization of HIV-1 VIF protein as a therapeutic target |
| 05/06/2004 | US20040086508 Administering to the patient an effective amount of an antibody that specifically binds interferon gamma and an antibody that specifically binds tumor necrosis factor alpha |
| 05/06/2004 | US20040086507 Antibody inhibiting vplf activity |
| 05/06/2004 | US20040086504 Antibodies which neutralize Cyr61 activity, a growth factor-regulated immediate-early genes that play a role in development, cell proliferation, and tumorigenesis |
| 05/06/2004 | US20040086503 High-affinity human anti-IGF-IR antibodies that could be used to treat diseases in humans |
| 05/06/2004 | US20040086502 Has a binding affinity for a target antigen which is at least about two fold stronger than the binding affinity of the parent antibody for said antigen |
| 05/06/2004 | US20040086500 Murabutide, an analog of muramyl dipeptide, induces the production of cytokines or other factors not identified to date, which have a suppressor activity on HIV |
| 05/06/2004 | US20040086455 Detection and treatment of cancer |
| 05/06/2004 | US20040084867 Individualization of therapy with anticoagulants |
| 05/06/2004 | EP1416281A2 Assay for disease related conformation of a protein |
| 05/06/2004 | EP1416280A2 Antibodies specific for native PrPsc |
| 05/06/2004 | EP1416272A1 Pael receptor, cells and animal expressing pael receptor and method of screening remedy for parkinson's disease |
| 05/06/2004 | EP1415998A2 Antibody fragment-polymer conjugates and humanized anti-IL-8 monoclonal antibodies |
| 05/06/2004 | EP1415659A1 BAFF, inhibitors thereof and their use in the modulation of the B-cell response |
| 05/06/2004 | EP1415154A2 Control of growth and repair of gastro-intestinal tissues by gastrokines and inhibitors |
| 05/06/2004 | EP1415006A2 Assay for identifying inhibitors of hiv rt dimerization |
| 05/06/2004 | EP1415005A2 Endogenous retroviruses up-regulated in prostate cancer |
| 05/06/2004 | EP1415002A2 Focussed antibody technology |
| 05/06/2004 | EP1414967A2 Gene associated with leishmania parasite virulence |
| 05/06/2004 | EP1414965A2 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |